Synthesis, Docking and Rho Kinase Inhibition of Novel Piperazine-7-Deazapurine Based Imidazolidone Derivatives

被引:0
作者
Thoota, Sandeep Kumar [1 ]
Maddila, Suresh [1 ,2 ]
Pindiprolu, Sai Kiran S. S. [3 ]
Kohli, Sukhmeen Kaur [4 ]
Reddy, Sujith Reddy [5 ]
Matsa, Sunil Kumar [6 ]
Jonnalagadda, Sreekantha B. [2 ]
机构
[1] GITAM Univ, GITAM Sch Sci, Dept Chem, Visakhapatnam 530045, Andhra Pradesh, India
[2] Univ KwaZulu Natal, Sch Chem & Phys, Westville Campus,Chiltern Hills, ZA-4000 Durban, South Africa
[3] Aditya Univ, Sch Pharm, Kakinada 533437, Andhra Pradesh, India
[4] Indian Inst Sci Educ & Res IISER Tirupati, Dept Earth & Climate Sci, Tirupati 517507, Andhra Pradesh, India
[5] Govt Degree Coll, Dept Chem, Mahabubabad 506101, Telangana, India
[6] Ayurveda Mol Modeling, Hyderabad 500003, Telangana, India
来源
CHEMISTRYSELECT | 2025年 / 10卷 / 01期
关键词
7-Deazapurine; Inhibitory assay; Pyrrolo[2,3-d]-pyrimidine; Rho kinase I & II; Synthesis; PROTEIN-KINASE; ROCK INHIBITORS; Y-27632; DISCOVERY; APOPTOSIS; GLAUCOMA; MUSCLE;
D O I
10.1002/slct.202403434
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
A new series of (Z)-2-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperazin-1-yl)-5-(benzylidene)-1,5-dihydro-4H-imidazol-4-ones (5a-t) has been synthesized via a seven-step pathway with various substituted benzaldehydes yielding various derivatives as ROCK inhibitors. H-1 NMR, C-13 NMR, and HRMS spectral analysis were used to describe all the novel target compounds. We examined the effects of various aromatic substitutions on the inhibition of ROCK-I & ROCK-II using molecular modeling analysis. Although molecular docking revealed a range of binding affinities, a majority of the synthesized compounds demonstrated low inhibitory activities (pIC(50) < 6.0), with no significant improvement over CCT129254 (4). This investigation highlights the complexities in developing potent and selective ROCK inhibitors and lays the groundwork for future enhancements in cancer therapeutics.
引用
收藏
页数:9
相关论文
共 58 条
  • [1] Abdel-Magid Ahmed F, 2019, ACS Med Chem Lett, V10, P841, DOI 10.1021/acsmedchemlett.9b00214
  • [2] Abdel-Magid Ahmed F, 2015, ACS Med Chem Lett, V6, P371, DOI 10.1021/acsmedchemlett.5b00079
  • [3] Alessandra B., 2008, [No title captured], Patent No. [WO2008054599, 2008054599]
  • [4] Rho-kinase: regulation, (dys) function, and inhibition
    Amin, Ehsan
    Dubey, Badri Nath
    Zhang, Si-Cai
    Gremer, Lothar
    Dvorsky, Radovan
    Moll, Jens M.
    Taha, Mohamed S.
    Nagel-Steger, Luitgard
    Piekorz, Roland P.
    Somlyo, Avril V.
    Ahmadian, Mohammad R.
    [J]. BIOLOGICAL CHEMISTRY, 2013, 394 (11) : 1399 - 1410
  • [5] Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity
    Anastassiadis, Theonie
    Deacon, Sean W.
    Devarajan, Karthik
    Ma, Haiching
    Peterson, Jeffrey R.
    [J]. NATURE BIOTECHNOLOGY, 2011, 29 (11) : 1039 - U117
  • [6] ROCK inhibitors 4: Structure-activity relationship studies of 7-azaindole-based rho kinase (ROCK) inhibitors
    Bandarage, Upul K.
    Court, John
    Gao, Huai
    Nanthakumar, Suganthini
    Come, Jon H.
    Giroux, Simon
    Green, Jeremy
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2021, 33
  • [7] Preclinical to clinical utility of ROCK inhibitors in cancer
    Barcelo, Jaume
    Samain, Remi
    Sanz-Moreno, Victoria
    [J]. TRENDS IN CANCER, 2023, 9 (03) : 250 - 263
  • [8] Substituted 2H-isoquinolin-1-ones as potent Rho-kinase inhibitors: Part 3, aryl substituted pyrrolidines
    Bosanac, Todd
    Hickey, Eugene R.
    Ginn, John
    Kashem, Mohammed
    Kerr, Steven
    Kugler, Stanley
    Li, Xiang
    Olague, Alan
    Schlyer, Sabine
    Young, Erick R. R.
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (12) : 3746 - 3749
  • [9] Cucurbitacin IIa: a novel class of anti-cancer drug inducing non-reversible actin aggregation and inhibiting survivin independent of JAK2/STAT3 phosphorylation
    Boykin, C.
    Zhang, G.
    Chen, Y-H
    Zhang, R-W
    Fan, X-E
    Yang, W-M
    Lu, Q.
    [J]. BRITISH JOURNAL OF CANCER, 2011, 104 (05) : 781 - 789
  • [10] The role of the RhoA/Rho kinase pathway in angiogenesis and its potential value in prostate cancer (Review)
    Chen, Weihua
    Mao, Kaili
    Liu, Zhongmin
    Anh Tuan Dinh-Xuan
    [J]. ONCOLOGY LETTERS, 2014, 8 (05) : 1907 - 1911